Discovery of non-nucleoside inhibitors of HIV-1 reverse transcriptase competing with the nucleotide substrate

被引:19
作者
Maga, Giovanni
Radi, Marco
Zanoli, Samantha
Manetti, Fabrizio
Cancio, Reynel
Huebscher, Ulrich
Spadari, Silvio
Falciani, Chiara
Terrazas, Montserrat
Vilarrasa, Jaume
Botta, Maurizio
机构
[1] Univ Siena, Dipartimento Farmaco Chim Tecnol, I-53100 Siena, Italy
[2] CNR, IGM, I-27100 Pavia, Italy
[3] Univ Zurich Irchel, Inst Vet Biochem & Mol Biol, CH-8092 Zurich, Switzerland
[4] Univ Barcelona, Fac Quim, Dept Quim Organ, E-08028 Barcelona, Spain
关键词
HIV-1 reverse transcriptase; competitive inhibitors; drug design; enzymes; pyrimidines;
D O I
10.1002/anie.200604165
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
How odd! A new class of non-nucleoside reverse transcriptase inhibitors with a 6-vinylpyrimidine scaffold (1) has been found to inhibit HIV-1 reverse transcriptase (RT) by competition with the nucleotide substrate after binding to the non-nucleoside inhibitor binding pocket of the enzyme. Molecular modeling studies have been performed to elucidate their peculiar behavior. (Figure Presented). © 2007 Wiley-VCH Verlag GmbH & Co. KGaA.
引用
收藏
页码:1810 / 1813
页数:4
相关论文
共 13 条
[1]   HIV-1-SPECIFIC REVERSE-TRANSCRIPTASE INHIBITORS SHOW DIFFERENTIAL ACTIVITY AGAINST HIV-1 MUTANT STRAINS CONTAINING DIFFERENT AMINO-ACID SUBSTITUTIONS IN THE REVERSE-TRANSCRIPTASE [J].
BALZARINI, J ;
KARLSSON, A ;
PEREZPEREZ, MJ ;
VRANG, L ;
WALBERS, J ;
ZHANG, H ;
OBERG, B ;
VANDAMME, AM ;
CAMARASA, MJ ;
DECLERCQ, E .
VIROLOGY, 1993, 192 (01) :246-253
[2]   Highly active antiretroviral therapy-associated metabolic syndrome and cardiovascular risk [J].
Barbaro, Giuseppe ;
Barbarini, Giorgio .
CHEMOTHERAPY, 2006, 52 (04) :161-165
[3]  
BOTTA M, 2005, Patent No. 2005A000512
[4]   Crystallography and the design of anti-AIDS drugs: Conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors [J].
Das, K ;
Lewi, PJ ;
Hughes, SH ;
Arnold, E .
PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY, 2005, 88 (02) :209-231
[5]   Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants [J].
Das, K ;
Clark, AD ;
Lewi, PJ ;
Heeres, J ;
de Jonge, MR ;
Koymans, LMH ;
Vinkers, HM ;
Daeyaert, F ;
Ludovici, DW ;
Kukla, MJ ;
De Corte, B ;
Kavash, RW ;
Ho, CY ;
Ye, H ;
Lichtenstein, MA ;
Andries, K ;
Pauwels, R ;
de Béthune, MP ;
Boyer, PL ;
Clark, P ;
Hughes, SH ;
Janssen, PAJ ;
Arnold, E .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (10) :2550-2560
[6]   STRUCTURE OF HIV-1 RT/TIBO R-86183 COMPLEX REVEALS SIMILARITY IN THE BINDING OF DIVERSE NONNUCLEOSIDE INHIBITORS [J].
DING, JP ;
DAS, K ;
MOEREELS, H ;
KOYMANS, L ;
ANDRIES, K ;
JANSSEN, PAJ ;
HUGHES, SH ;
ARNOLD, E .
NATURE STRUCTURAL BIOLOGY, 1995, 2 (05) :407-415
[7]   Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors [J].
Hopkins, AL ;
Ren, JS ;
Esnouf, RM ;
Willcox, BE ;
Jones, EY ;
Ross, C ;
Miyasaka, T ;
Walker, RT ;
Tanaka, H ;
Stammers, DK ;
Stuart, DI .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (08) :1589-1600
[8]   Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant [J].
Lindberg, J ;
Sigurdsson, S ;
Löwgren, S ;
Andersson, HO ;
Sahlberg, C ;
Noréen, R ;
Fridborg, K ;
Zhang, H ;
Unge, T .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 2002, 269 (06) :1670-1677
[9]  
MELLORS JW, 1992, MOL PHARMACOL, V41, P446
[10]   VIRAL RESISTANCE TO HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1-SPECIFIC PYRIDINONE REVERSE-TRANSCRIPTASE INHIBITORS [J].
NUNBERG, JH ;
SCHLEIF, WA ;
BOOTS, EJ ;
OBRIEN, JA ;
QUINTERO, JC ;
HOFFMAN, JM ;
EMINI, EA ;
GOLDMAN, ME .
JOURNAL OF VIROLOGY, 1991, 65 (09) :4887-4892